GEN Exclusives

More »

GEN News Highlights

Back to Item »

Abraxis Reports Phase III Success with Abraxane in First-Line NSCLC

Nab-paclitaxel in combination with carboplatin enhanced ORR by 31%.

Forward this item to a colleague:


(Separate multiple addresses by commas)


(Separate multiple addresses by commas)


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Value-Pricing Cancer Drugs

Do you think all new cancer drugs awaiting approval should undergo value-pricing?

More »